Schito G C, Chezzi C, Nicoletti G, Moreddu M, Arcangeletti M C, Stefani S, Albini E, Del Bono G P
Istituto di Microbiologia, Università degli Studi di Genova, Italy.
Infection. 1992;20 Suppl 4:S291-5. doi: 10.1007/BF01710017.
In order to assess the resistance profile for fosfomycin trometamol after several years of clinical use in Italy, this study has explored the susceptibility to fosfomycin and eight other antibacterial drugs of 6,021 strains isolated from 23,816 urines during 1990 in three teaching hospitals located in Genoa, Parma and Catania. Gram-negative strains, notably Escherichia coli (41.6%), were primarily involved. Amoxicillin was the least active compound with resistance in 41.4% of the isolates. Fosfomycin showed the lowest rate of resistance in both gram-negative (2.8%) and gram-positive (2.1%) pathogens. This was followed by norfloxacin with a resistance rate of 11.8% and netilmicin with 12.2%. These results indicate that fosfomycin-trometamol may continue to be used in single-dose treatment of urinary tract infections even in the absence of microbiological data since the prevalence of resistance to the drug is, at present, so low that therapeutic failure is highly improbable.
为评估在意大利临床使用数年后的磷霉素氨丁三醇的耐药情况,本研究探讨了1990年从热那亚、帕尔马和卡塔尼亚的三家教学医院的23816份尿液中分离出的6021株菌株对磷霉素及其他八种抗菌药物的敏感性。革兰氏阴性菌,尤其是大肠杆菌(41.6%),是主要涉及的菌株。阿莫西林是活性最低的化合物,41.4%的分离株对其耐药。磷霉素在革兰氏阴性菌(2.8%)和革兰氏阳性菌(2.1%)病原体中的耐药率最低。其次是诺氟沙星,耐药率为11.8%,奈替米星为12.2%。这些结果表明,即使没有微生物学数据,磷霉素氨丁三醇仍可继续用于单剂量治疗尿路感染,因为目前该药物的耐药率很低,治疗失败的可能性极小。